Takeda Faces Arbitration Over Antitrust Allegations in Pay-for-Delay Drug Deal

In a legal development, Meijer’s claims against Takeda Pharmaceutical Corporation will proceed to arbitration. The suit centers around allegations that Takeda entered a pay-for-delay agreement with Par Pharmaceuticals. This alleged deal reportedly aimed to postpone the market entry of a generic variant of Amitiza, Takeda’s anti-constipation drug, for an extended period. Antitrust concerns have emerged regarding the potential impact of such arrangements on market competition and drug prices. For further details on this case, you can view the original article on Law360.